The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bramazil     (E)-N,6,6-trimethyl-N- (naphthalen-1...

Synonyms: Corbinal, Terbinex, Lamasil, Lamisil, TerbiFoam, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lamisil


Psychiatry related information on Lamisil


High impact information on Lamisil

  • The quadruple mutant, however, was more sensitive to terbinafine, an inhibitor of Erg1p, than the are1are2 strain suggesting that the presence of TAG and/or intact lipid particles has an additional protective effect [11].
  • Overexpression/selection using the sterol synthesis inhibitors terbinafine (TBF, targeting squalene epoxidase) and itraconazole (ITZ, targeting lanosterol C(14)-demethylase) yielded nine new resistance loci [12].
  • Rat SE cDNA was isolated by selecting yeast transformants expressing rat cDNA in the presence of transformants expressing rat cDNA in the presence of terbinafine, an inhibitor specific for fungal SE [13].
  • (vi) Treatment of S. cerevisiae with azole or terbinafine resulted in transcriptional upregulation of genes FKS2 and PMR1 known to be Ca2+ regulated [14].
  • Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis [15].

Chemical compound and disease context of Lamisil


Biological context of Lamisil


Anatomical context of Lamisil


Associations of Lamisil with other chemical compounds


Gene context of Lamisil


Analytical, diagnostic and therapeutic context of Lamisil


  1. Terbinafine and fulminant hepatic failure. Agarwal, K., Manas, D.M., Hudson, M. N. Engl. J. Med. (1999) [Pubmed]
  2. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Petranyi, G., Ryder, N.S., Stütz, A. Science (1984) [Pubmed]
  3. Treatment of seborrhoeic dermatitis with oral terbinafine? Faergemann, J. Lancet (2001) [Pubmed]
  4. Terbinafine for black piedra. Gip, L. Lancet (1993) [Pubmed]
  5. Desipramine toxicity with terbinafine. O'Reardon, J.P., Hetznecker, J.M., Rynn, M.A., Baldassano, C.F., Szuba, M.P. The American journal of psychiatry. (2002) [Pubmed]
  6. Treatment of cutaneous sporotrichosis with terbinafine. Hull, P.R., Vismer, H.F. Br. J. Dermatol. (1992) [Pubmed]
  7. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Bräutigam, M., Nolting, S., Schopf, R.E., Weidinger, G. Br. J. Dermatol. (1996) [Pubmed]
  8. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. Avner, S., Nir, N., Henri, T. The Journal of dermatological treatment. (2005) [Pubmed]
  9. The use of oral terbinafine (Lamisil) in children. Krafchik, B., Pelletier, J. Dermatology (Basel) (1997) [Pubmed]
  10. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. Potter, L.P., Mathias, S.D., Raut, M., Kianifard, F., Landsman, A., Tavakkol, A. The Journal of dermatological treatment (2007) [Pubmed]
  11. A yeast strain lacking lipid particles bears a defect in ergosterol formation. Sorger, D., Athenstaedt, K., Hrastnik, C., Daum, G. J. Biol. Chem. (2004) [Pubmed]
  12. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection. Cotrim, P.C., Garrity, L.K., Beverley, S.M. J. Biol. Chem. (1999) [Pubmed]
  13. Molecular cloning and expression of rat squalene epoxidase. Sakakibara, J., Watanabe, R., Kanai, Y., Ono, T. J. Biol. Chem. (1995) [Pubmed]
  14. Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Edlind, T., Smith, L., Henry, K., Katiyar, S., Nickels, J. Mol. Microbiol. (2002) [Pubmed]
  15. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Anania, F.A., Rabin, L. Am. J. Med. (2002) [Pubmed]
  16. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria, M., Bryson, H.M., Goa, K.L. Drugs (1996) [Pubmed]
  17. Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. Sorensen, K.N., Sobel, R.A., Clemons, K.V., Calderon, L., Howell, K.J., Irani, P.R., Pappagianis, D., Williams, P.L., Stevens, D.A. Antimicrob. Agents Chemother. (2000) [Pubmed]
  18. Terbinafine. An update of its use in superficial mycoses. McClellan, K.J., Wiseman, L.R., Markham, A. Drugs (1999) [Pubmed]
  19. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Maldonado, R.A., Molina, J., Payares, G., Urbina, J.A. Antimicrob. Agents Chemother. (1993) [Pubmed]
  20. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Tatsumi, Y., Yokoo, M., Senda, H., Kakehi, K. Antimicrob. Agents Chemother. (2002) [Pubmed]
  21. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Saari, T.I., Laine, K., Leino, K., Valtonen, M., Neuvonen, P.J., Olkkola, K.T. Clin. Pharmacol. Ther. (2006) [Pubmed]
  22. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Abdel-Rahman, S.M., Gotschall, R.R., Kauffman, R.E., Leeder, J.S., Kearns, G.L. Clin. Pharmacol. Ther. (1999) [Pubmed]
  23. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Walzer, P.D., Ashbaugh, A. Antimicrob. Agents Chemother. (2002) [Pubmed]
  24. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Osborne, C.S., Leitner, I., Favre, B., Ryder, N.S. Antimicrob. Agents Chemother. (2005) [Pubmed]
  25. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Kovarik, J.M., Mueller, E.A., Zehender, H., Denouël, J., Caplain, H., Millerioux, L. Antimicrob. Agents Chemother. (1995) [Pubmed]
  26. Inhibition of human vascular endothelial cells proliferation by terbinafine. Ho, P.Y., Liang, Y.C., Ho, Y.S., Chen, C.T., Lee, W.S. Int. J. Cancer (2004) [Pubmed]
  27. Pharmacokinetics of antifungal agents in onychomycoses. Debruyne, D., Coquerel, A. Clinical pharmacokinetics. (2001) [Pubmed]
  28. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Lazardi, K., Urbina, J.A., de Souza, W. Antimicrob. Agents Chemother. (1990) [Pubmed]
  29. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Hosseini-Yeganeh, M., McLachlan, A.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  30. In vitro comparison of terbinafine and itraconazole against Penicillium marneffei. McGinnis, M.R., Nordoff, N.G., Ryder, N.S., Nunn, G.B. Antimicrob. Agents Chemother. (2000) [Pubmed]
  31. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Cantón, E., Pemán, J., Gobernado, M., Viudes, A., Espinel-Ingroff, A. Antimicrob. Agents Chemother. (2005) [Pubmed]
  32. Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function. Nussbaumer, P., Leitner, I., Mraz, K., Stütz, A. J. Med. Chem. (1995) [Pubmed]
  33. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Moore, C.B., Walls, C.M., Denning, D.W. Antimicrob. Agents Chemother. (2001) [Pubmed]
  34. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Favre, B., Ryder, N.S. Antimicrob. Agents Chemother. (1996) [Pubmed]
  35. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest. Lee, W.S., Chen, R.J., Wang, Y.J., Tseng, H., Jeng, J.H., Lin, S.Y., Liang, Y.C., Chen, C.H., Lin, C.H., Lin, J.K., Ho, P.Y., Chu, J.S., Ho, W.L., Chen, L.C., Ho, Y.S. Int. J. Cancer (2003) [Pubmed]
  36. Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Klobucníková, V., Kohút, P., Leber, R., Fuchsbichler, S., Schweighofer, N., Turnowsky, F., Hapala, I. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  37. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase. Trépanier, E.F., Nafziger, A.N., Kearns, G.L., Kashuba, A.D., Amsden, G.W. Journal of clinical pharmacology. (1998) [Pubmed]
  38. ROX1 and ERG regulation in Saccharomyces cerevisiae: implications for antifungal susceptibility. Henry, K.W., Nickels, J.T., Edlind, T.D. Eukaryotic Cell (2002) [Pubmed]
  39. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Balfour, J.A., Faulds, D. Drugs (1992) [Pubmed]
  40. Bioassay for SF 86-327, a new antifungal agent. Kan, V.L., Henderson, D.K., Bennett, J.E. Antimicrob. Agents Chemother. (1986) [Pubmed]
  41. Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient. Walter, R.B., Lukaschek, J., Renner, E.L., Müllhaupt, B., Bachli, E.B. J. Hepatol. (2003) [Pubmed]
  42. Terbinafine-associated hepatic injury. van 't Wout, J.W., Herrmann, W.A., de Vries, R.A., Stricker, B.H. J. Hepatol. (1994) [Pubmed]
WikiGenes - Universities